Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > CIRO

<< Previous

Bullboard Posts

Next >>

Post by Ingiboyon Mar 13, 2024 1:10pm

103 Views

Post# 35930865

CIRO

I think the time has come for some answers. They can no longer hide behind any legal restrictions.
This is verging on becoming a matter for the Canadian Investment Regulatory Organization (CIRO).

Major decisions are being made regarding Replicel without consulting the shareholders and that is illegal in my view. The time has come for all of us bewildered shareholders to do a full court press on the managment of this company.
The Replicel website lists a phone number: 604 248 8730.

We as a group now need to ask for some answers.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario